<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> was initially described in 1986 </plain></SENT>
<SENT sid="1" pm="."><plain>To reassess the validity of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 95 patients with SLE were studied </plain></SENT>
<SENT sid="2" pm="."><plain>Their <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> profile was analysed and correlated with clinical findings such as <z:mp ids='MP_0005048'>thrombosis</z:mp>, abortions, or <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A low prevalence of these antibodies was found (13 patients; 14%) with a high specificity for <z:mp ids='MP_0005048'>thrombosis</z:mp> (92%) and abortions (92%) </plain></SENT>
<SENT sid="4" pm="."><plain>The importance of anticardiolipin antibodies as a risk factor for <z:mp ids='MP_0005048'>thrombosis</z:mp> or abortions, or both, in patients with SLE is reaffirmed by this work </plain></SENT>
</text></document>